What Is the Average Dose of Ozempic for Weight Loss?

Ozempic is prescribed in doses of 0.5 mg, 1 mg, or 2 mg injected once weekly, with most people using it off-label for weight loss eventually reaching 1 mg or 2 mg per week after a gradual ramp-up period. The catch is that Ozempic is technically approved for type 2 diabetes, not weight management. Its active ingredient, semaglutide, is the same molecule found in Wegovy, which is approved for weight loss at a higher weekly dose of 2.4 mg. That distinction matters more than it might seem, and the dosing picture gets more interesting once you look at how titration works, what the clinical trials actually tested, and why not everyone ends up on the same dose.

Why Ozempic and Wegovy Are the Same Drug at Different Doses

Both Ozempic and Wegovy contain semaglutide, a lab-modified version of a gut hormone called GLP-1 that slows digestion, curbs appetite, and helps regulate blood sugar. Ozempic was developed and approved as a diabetes medication, while Wegovy was positioned as a weight-loss treatment. The practical difference for dosing is that Ozempic’s pen tops out at 2 mg per week, while Wegovy’s titration schedule climbs to 2.4 mg per week. When someone asks about “the average dose of Ozempic for weight loss,” they’re usually asking about off-label Ozempic use, where the maximum available dose is 2 mg, or they’re conflating the two brands. Either way, the weight-loss evidence from large trials was generated at the 2.4 mg dose available only through Wegovy.

The Titration Schedule

Nobody starts semaglutide at the target dose. The standard approach is a slow climb over several weeks to give your gut time to adjust. For Ozempic, the label-recommended titration begins at 0.25 mg weekly for four weeks, then bumps to 0.5 mg for another four weeks, and finally to 1 mg. From there, a prescriber may increase to 2 mg if more blood-sugar control or weight loss is needed. Each step lasts at least four weeks because semaglutide has a half-life of about a week, meaning the drug takes four to five weeks to reach a stable level in your blood at any given dose.¹ Jumping ahead before the body adjusts is a reliable way to trigger nausea, vomiting, or other gastrointestinal misery.

Some clinicians are experimenting with even slower titration. A pilot trial randomized people with type 2 diabetes to either the standard 4-week step-ups or a flexible schedule that started at a tiny dose of about 0.07 mg and increased by that amount each week, pausing whenever gastrointestinal symptoms flared.² The logic is straightforward: if side effects are the main reason people quit, slowing the ramp-up could keep more patients on the drug long enough to benefit.

What “Maintenance Dose” Actually Means for Weight Loss

When Ozempic is used off-label for weight loss, most prescribers aim for the highest tolerated dose, which is typically 1 mg or 2 mg per week. But the landmark clinical trials that established semaglutide as a weight-loss drug tested a 2.4 mg weekly dose, the dose only available as Wegovy. In the STEP 1 trial, participants on 2.4 mg semaglutide lost about 15% of their body weight over 68 weeks, compared with roughly 2.4% in the placebo group.³ About half of the semaglutide group lost 15% or more of their starting weight, which is a threshold that often produces meaningful improvements in blood pressure, cholesterol, and blood sugar.

Those results held up over longer timeframes. In the STEP 5 trial, which followed participants for two years, the semaglutide group maintained an average weight loss of about 15% at the 104-week mark.⁴ That consistency over two years matters because many weight-loss interventions show initial promise but fade. Semaglutide at the full 2.4 mg dose has held up across all the phase 3 STEP trials.⁵

If you’re on Ozempic at 1 mg or even 2 mg rather than Wegovy at 2.4 mg, you should expect less dramatic results than what the STEP trials reported. The weight loss is dose-dependent, so lower doses generally produce less loss. Real-world data paints a more modest picture than clinical trials in general, partly because real-world patients skip doses, titrate more slowly, and don’t have the structured support of a trial environment.

How Staying on the Full Dose Compares to Stopping

The STEP 4 trial tackled a question many patients have: once you’ve lost weight, do you need to stay on the drug? All participants first spent 20 weeks titrating up to 2.4 mg semaglutide, then half were randomly switched to placebo while the other half continued. Those who stayed on semaglutide lost an additional 8% of body weight from week 20 to week 68, while those switched to placebo regained about 7%, a swing of roughly 15 percentage points.⁶ The message from this trial is clear: the maintenance dose is the dose you reached. Cutting back or stopping tends to reverse progress.

Data from the STEP 1 trial extension reinforced that. After semaglutide was withdrawn, participants regained about two-thirds of the weight they had lost within a year.⁷ That regain isn’t unique to semaglutide; it reflects the biology of obesity, where the body’s appetite and metabolic signals push hard to restore lost weight. The practical takeaway is that for most people, semaglutide for weight loss means ongoing treatment, not a temporary course.

Side Effects and Why Many People Don’t Reach the Top Dose

Gastrointestinal side effects are the main reason people either stay on a lower dose or quit entirely. Nausea is the most common complaint, followed by vomiting, diarrhea, and constipation. These symptoms tend to be worst during dose escalation and improve once the body adjusts, but not everyone adjusts. In a prospective observational study, about 58% of patients who experienced GI symptoms described them as mild, while roughly 28% needed a dose reduction to manage moderate symptoms, and about 14% stopped the drug altogether because of severe intolerance.⁸ Among those who did reduce their dose, about two-thirds were able to continue therapy successfully.

This means the “average dose” in practice often ends up being whatever dose a person can tolerate, which may be 0.5 mg, 1 mg, or 2 mg rather than the 2.4 mg tested in trials. Some prescribers will hold a patient at a lower dose for longer before attempting the next step up, while others will drop back a step if side effects become problematic. There is no single correct approach, and the variation in what people actually take explains some of the gap between clinical trial outcomes and real-world results.

Why People with Diabetes Tend to Lose Less Weight

One of the stronger findings in the semaglutide literature is that diabetes status significantly affects how much weight you lose. A meta-analysis comparing weight outcomes between people with and without type 2 diabetes found that non-diabetic participants lost about 15.7% of their body weight at 12 months, versus only 5.1% for diabetic participants taking the same drugs. Non-diabetic individuals achieved roughly 2.5 to 4 times greater weight reductions than diabetic individuals on the same agents, and meta-regression confirmed diabetes status as an independent negative predictor of weight loss.⁹

The reasons are not entirely settled, but insulin resistance and the metabolic environment of type 2 diabetes likely blunt the drug’s appetite-suppressing and fat-burning effects. This matters for dosing expectations: if you have diabetes and are prescribed Ozempic at 1 mg or 2 mg, a 5-6% weight loss may be a realistic outcome rather than the 15% figure from the headline trials, which enrolled mostly non-diabetic participants or used the higher 2.4 mg dose. It doesn’t mean the drug isn’t working. It means the same dose produces a different magnitude of effect depending on your metabolic starting point.

What Happens to Muscle When You Lose Weight on Semaglutide

A common concern with rapid weight loss from any cause is whether you’re losing fat, muscle, or both. A systematic review of six trials involving over 1,500 adults found that weight reductions on semaglutide were driven primarily by fat mass loss, though lean mass did decrease in some cases, accounting for anywhere from nearly 0% to 40% of total weight lost depending on the trial.¹⁰ An important nuance is that even when lean mass dropped in absolute terms, the proportion of lean mass relative to total body mass increased, meaning body composition improved overall.

The SEMALEAN study provided a more granular timeline. Participants lost an average of 10% of body weight at seven months and 13% at one year. Total fat mass dropped by 18% at 12 months. Lean mass did decline initially, with a loss of about 3 kilograms at the seven-month mark, but it stabilized after that.¹¹ More reassuringly, research in both mice and humans found that GLP-1 medicines improve body composition without negatively affecting strength.¹² Resistance training during treatment is still widely recommended by clinicians to preserve muscle, but the fear that semaglutide melts away muscle mass indiscriminately is not well supported by the data.

How Semaglutide Compares to Tirzepatide

If you’re weighing Ozempic against newer alternatives, tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) is the most relevant comparison. A systematic review and meta-analysis of head-to-head data found that tirzepatide produced about 4.6 percentage points more weight loss than semaglutide overall. Higher proportions of tirzepatide-treated participants hit the major weight-loss benchmarks: 5%, 10%, 15%, and 20% reductions.¹³ That advantage likely stems from tirzepatide targeting two hormone receptors instead of one.

Weight regain after stopping appears similar for both drugs. An analysis comparing monthly regain rates after discontinuation found that semaglutide users regained roughly 1% of body weight per month and tirzepatide users about 1.2% per month, with both groups recovering approximately two-thirds of their lost weight within a year of stopping.¹⁴ So while tirzepatide may produce more weight loss while you’re on it, neither drug appears to confer a lasting advantage once discontinued.

Why the Drug Lasts a Full Week

Part of what makes semaglutide practical as a weight-loss treatment is its unusually long half-life. At the 0.5 mg or 1 mg dose, semaglutide has a half-life of about seven days, which is why once-weekly dosing works and why each new dose adds to the drug still circulating from the previous injection.¹ Pharmacokinetic studies have confirmed a dose-corrected accumulation ratio of about 2, meaning that at steady state, the amount of drug in your system is roughly double what a single injection delivers.¹⁵ This accumulation is why the gradual titration matters so much: jumping to a high dose doesn’t just deliver more drug that day, it sets a higher plateau that builds over the coming weeks.

That long half-life also means that if you miss a dose, blood levels drop slowly. Most guidelines say you can take a missed dose within five days of the scheduled day. If more than five days have passed, skip it and take the next one on schedule. The slow clearance provides a buffer, but it also means side effects from a dose that’s too high can linger for days rather than hours.

The Risks of Compounded Semaglutide

During periods of brand-name shortage, some patients have turned to compounding pharmacies that mix their own semaglutide preparations. This introduces dosing risks that don’t exist with prefilled pens. A case series reported to a poison control center documented patients who self-administered tenfold dosing errors with compounded semaglutide. All experienced significant nausea, vomiting, and abdominal pain lasting for days. One patient received a vial and syringes with no pharmacist counseling, and another reported measuring the dose in milliliters and units rather than milligrams, a confusion that’s almost impossible with the branded pens’ dial-based dosing system.⁵

The branded Ozempic and Wegovy pens are designed to make dosing errors difficult. You click a dial to the prescribed dose, and the pen delivers exactly that amount. Compounded vials require drawing up liquid with a syringe, a process where the concentration of the solution, the volume in the syringe, and the units on the syringe barrel all have to align correctly. If any of those are misunderstood, you can easily end up injecting several times the intended dose. For a drug where even the correct next step up can cause days of nausea, an accidental tenfold overdose is a serious event.

Individual Variation in Response

Even among people on the same dose, weight loss varies widely. Researchers have built exposure-response models using baseline demographics, blood sugar markers, and drug-level data to try to predict who will lose more and who will lose less on semaglutide.¹⁶ While these models are still research tools rather than clinical decision-aids, they highlight that starting weight, metabolic health, and how much drug actually reaches your bloodstream all influence outcomes. Two people on identical 2 mg weekly doses can have meaningfully different circulating drug levels and very different weight trajectories.

This variability is one reason prescribers sometimes keep a patient at a moderate dose if it’s producing good results, rather than pushing to the maximum. If you’re losing weight steadily at 1 mg with manageable side effects, the benefit of escalating to 2 mg may not be worth the increased GI symptoms for you specifically. Conversely, someone who plateaus at 1 mg with no side effects at all is a reasonable candidate for a dose increase. The “right” dose is less about population averages and more about the intersection of your response, your tolerance, and your goals.